Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.560
-0.130 (-2.77%)
At close: May 26, 2026, 4:00 PM EDT
4.660
+0.100 (2.19%)
Pre-market: May 27, 2026, 4:00 AM EDT
Achieve Life Sciences Market Cap
Achieve Life Sciences has a market cap or net worth of $468.13 million as of May 26, 2026. Its market cap has increased by 474.39% in one year.
Market Cap
468.13M
Enterprise Value
453.81M
1-Year Change
474.39%
Ranking
Category
Stock Price
$4.56
Market Cap Chart
Since December 1, 1998, Achieve Life Sciences's market cap has increased from $67.40M to $468.13M, an increase of 594.55%. That is a compound annual growth rate of 7.30%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 26, 2026 | 468.10M | 76.91% |
| Dec 31, 2025 | 264.60M | 118.50% |
| Dec 31, 2024 | 121.10M | 38.88% |
| Dec 29, 2023 | 87.20M | 266.39% |
| Dec 30, 2022 | 23.80M | -67.62% |
| Dec 31, 2021 | 73.50M | 150.85% |
| Dec 31, 2020 | 29.30M | 565.91% |
| Dec 31, 2019 | 4.40M | -45.68% |
| Dec 31, 2018 | 8.10M | -49.38% |
| Dec 29, 2017 | 16.00M | 6.67% |
| Dec 30, 2016 | 15.00M | -58.45% |
| Dec 31, 2015 | 36.10M | -25.87% |
| Dec 31, 2014 | 48.70M | -60.31% |
| Dec 31, 2013 | 122.70M | -36.19% |
| Dec 31, 2012 | 192.30M | 68.09% |
| Dec 30, 2011 | 114.40M | -29.47% |
| Dec 31, 2010 | 162.20M | 20.59% |
| Dec 31, 2009 | 134.50M | 715.15% |
| Dec 31, 2008 | 16.50M | 1.23% |
| Dec 31, 2007 | 16.30M | -92.75% |
| Dec 29, 2006 | 224.80M | 47.89% |
| Dec 30, 2005 | 152.00M | 101.86% |
| Dec 31, 2004 | 75.30M | -17.34% |
| Dec 31, 2003 | 91.10M | 214.14% |
| Dec 31, 2002 | 29.00M | -68.75% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eupraxia Pharmaceuticals | 488.65M |
| Shattuck Labs | 468.52M |
| 4D Molecular Therapeutics | 455.33M |
| Adlai Nortye | 454.00M |
| Sutro Biopharma | 453.63M |
| Ocugen | 453.62M |
| Fulcrum Therapeutics | 450.44M |
| Autolus Therapeutics | 447.12M |